Irosustat clinical trials
Also written BN83495 and STX64.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses irosustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Studies
Open first, then newest update. How each study uses irosustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- BN83495 Phase I in Post-menopausal WomenCompletedPhase 1IpsenNCT01840488Written as Irosustat (BN83495)How we know
- The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial CancerCompletedPhase 2IpsenNCT00910091Written as BN83495How we know
- BN83495 in Prostate CancerCompletedPhase 1IpsenNCT00790374Written as BN83495 (Cohort 1)How we know
- Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapyTerminatedPhase 2IpsenNCT01251354Written as BN83495How we know
- Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast CancerTerminatedPhase 2IpsenNCT01230970Written as BN83495How we know
- A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer GrowthTerminatedPhase 2Imperial College LondonNCT01662726Written as IrosustatHow we know
- A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.CompletedPhase 2Imperial College LondonNCT01785992Written as IrosustatHow we know
Codes
What other systems call irosustat · ClinicalTrials.gg INT005099
- MeSH (NLM) C520511irosustatOne source NLM
- UNII (FDA) 366037O6O7IROSUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27093313irosustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79827IrosustatOne source FDA
- DrugBank DB02292One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520511 | irosustat | One source NLM |
| UNII (FDA) | 366037O6O7 | IROSUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27093313 | irosustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79827 | Irosustat | One source FDA |
| DrugBank | DB02292 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.